APOE4 carriers are given a lower dose of certain drugs due to the risk of amyloid-related imaging abnormalities (ARIA).

“we know that with these amyloid drugs that remove amyloid we often will see changes in mri either edema or swelling or microhemorrhages so arya e for edema aria h for hemorrhages often asymptomatic but certainly were very significant in some of the earlier iterations of anti-amyloid drugs and drug trials that were going on and there was a distinct difference between the risk of arya and e4 carriers versus not”

“and there was a distinct difference between the risk of arya and e4 carriers versus not”

“often asymptomatic but certainly um were very significant in some of the earlier iterations of anti-amyloid drugs and drug trials that were going on”

“one of the reasons that they give the apo e4 carriers a lower dose is because of the risk of arya or amyloid related imaging abnormalities so we know that with these amyloid drugs that remove amyloid we often will see changes in mri either edema or swelling or microhemorrhages”